Want to see HK:2563 full AI Analyst Report?
2563 Stock Chart & Stats
HK$6.36
HK$0.54(3.44%)
At close: 4:00 PM EST
HK$6.36
HK$0.54(3.44%)
Day’s Range― - ―
52-Week RangeHK$2.40 - HK$9.63
Previous CloseN/A
Volume105.40K
Average Volume (3M)41.17K
Market Cap
HK$1.38B
Enterprise ValueHK$128.25M
Total Cash (Recent Filing)HK$565.53M
Total Debt (Recent Filing)HK$2.45M
Price to Earnings (P/E)―
Beta0.44
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding389,588,000
10 Day Avg. Volume43,120
30 Day Avg. Volume41,166
Financial Highlights & Ratios
PEG Ratio1.35
Price to Book (P/B)2.41
Price to Sales (P/S)48.10
P/FCF Ratio-10.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsSustained product-level margins near 90% indicate durable unit profitability and pricing power or a favorable product mix. This margin cushion supports recovery scenarios: if operating costs are controlled or revenues stabilize, profitability can improve faster than peers due to very high gross profit per sale.
Conservative Balance Sheet (low Leverage)Minimal financial leverage materially reduces near-term solvency and interest burden, giving management flexibility to fund operations via equity or partnerships. Over the medium term this lowers default risk and preserves optionality for R&D or regulatory timelines when cash needs arise.
Sizable Equity CushionA material equity base provides a capital buffer to absorb continued losses and supports continuity of operations while management pursues commercialization or cost restructuring. This equity cushion lengthens runway relative to similarly loss-making peers with higher leverage.
Bears Say
Consistent Negative Operating And Free Cash FlowPersistent cash burn requires ongoing external funding or asset sales, increasing dilution risk and constraining strategic choices. Even with low debt, negative OCF/FCF erodes cash reserves and limits the company’s ability to invest in scaling, regulatory milestones, or commercialization without new capital.
Deep, Recurring Net LossesSevere negative margins reflect operating cost structure well above revenues and indicate weak operating leverage. Persistent losses reduce strategic flexibility, raise likelihood of equity raises, and imply that without sustained revenue recovery or major cost reduction, route to profitability is uncertain.
Volatile And Sharply Declining RevenueA 51% year-over-year decline and overall top-line volatility signal demand, execution, or product issues that undermine predictability. High gross margins cannot translate to profits if sales fall; volatility complicates planning for R&D, commercialization, and cost absorption over the medium term.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H News
2563 FAQ
What was Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H lowest stock price was HK$2.40 and its highest was HK$9.63 in the past 12 months.
What is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s market cap?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s market cap is HK$1.38B.
When is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Beijing Biostar Pharmaceuticals Co., Ltd. Class H overvalued?
According to Wall Street analysts Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price is currently Overvalued.
Does Beijing Biostar Pharmaceuticals Co., Ltd. Class H pay dividends?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H does not currently pay dividends.
What is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s EPS estimate?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Biostar Pharmaceuticals Co., Ltd. Class H have?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H has 389,588,000 shares outstanding.
What happened to Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Beijing Biostar Pharmaceuticals Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2563
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) Earnings & Revenues
Technical Analysis
Luye Pharma Group
―
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
―
CANbridge Pharmaceuticals Inc.
―
Fangzhou Inc.
―
Hangzhou Jiuyuan Gene Engineering Co Ltd Class H
―